Showing results (11-20 of 26) with videos related to

Sort By:
Pageof 3
The Oncologist|June 2, 2018
Ramucirumab Plus Pembrolizumab in Patients with Previously Treated Advanced or Metastatic Biliary Tract Cancer: Nonrandomized, Open-Label, Phase I Trial (JVDF)Hendrik-Tobias Arkenau, Juan Martin-Liberal, Emiliano Calvo, et al.
Leukemia Research|September 22, 2017
A phase 1 study of the Janus kinase 2 (JAK2)<sup>V617F</sup> inhibitor, gandotinib (LY2784544), in patients with primary myelofibrosis, polycythemia vera, and essential thrombocythemiaSrdan Verstovsek, Ruben A Mesa, Mohamed E Salama, et al.
American Journal of Hematology|August 4, 2009
A phase II study of 5-day intravenous azacitidine in patients with myelodysplastic syndromesMike G Martin, Richard A Walgren, Elizabeth Procknow, et al.
Blood|March 21, 2009
Genome-wide association study to identify novel loci associated with therapy-related myeloid leukemia susceptibilityJeffrey A Knight, Andrew D Skol, Abhijit Shinde, et al.
Current Medical Research and Opinion|July 7, 2021
Clinical development and evaluation of a VEGF-D assay in plasma from patients with metastatic colorectal cancer in the RAISE studyHiroya Taniguchi, Takayuki Yoshino, Kensei Yamaguchi, et al.
Blood|February 16, 2023
Preclinical characterization of pirtobrutinib, a highly selective, noncovalent (reversible) BTK inhibitorEliana B Gomez, Kevin Ebata, Hetal S Randeria, et al.
British Journal of Clinical Pharmacology|January 14, 2022
Exposure-response relationship of ramucirumab in RANGE, a randomized phase III trial in advanced urothelial carcinoma refractory to platinum therapyRonald de Wit, Thomas Powles, Daniel Castellano, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 2, 2016
Docetaxel As Monotherapy or Combined With Ramucirumab or Icrucumab in Second-Line Treatment for Locally Advanced or Metastatic Urothelial Carcinoma: An Open-Label, Three-Arm, Randomized Controlled Phase II TrialDaniel P Petrylak, Scott T Tagawa, Manish Kohli, et al.
Oncotarget|March 24, 2018
Merestinib (LY2801653) inhibits neurotrophic receptor kinase (NTRK) and suppresses growth of NTRK fusion bearing tumorsBruce W Konicek, Andrew R Capen, Kelly M Credille, et al.
Investigational New Drugs|January 1, 2013
LY2801653 is an orally bioavailable multi-kinase inhibitor with potent activity against MET, MST1R, and other oncoproteins, and displays anti-tumor activities in mouse xenograft modelsS Betty Yan, Victoria L Peek, Rose Ajamie, et al.
Pageof 3